文献速递腹部技术与安全CT

门静脉期增强CT检测中度肝脂肪变性:自动化人工智能工具的评估

Detection of Moderate Hepatic Steatosis on Portal Venous Phase Contrast-Enhanced CT: Evaluation Using an Automated Artificial Intelligence Tool.
PubMed 文献 · AJR Am J Roentgenol · 2023-07-19

本研究回顾性纳入2917例患者,使用自动化深度学习工具测量门静脉期增强CT的肝脏和脾脏衰减值,以平扫肝衰减<40 HU为参考标准检测至少中度肝脂肪变性。结果显示,增强后肝衰减的诊断性能(AUC=0.938)优于肝脾衰减差(AUC=0.832),脾脏衰减可能不需要用于评估至少中度肝脂肪变性。

要点

  • 门静脉期增强CT肝衰减<80 HU检测至少中度肝脂肪变性的敏感度77.8%、特异度93.2%。
  • 门静脉期增强CT肝衰减<90 HU的敏感度90.5%、特异度78.4%。
  • 增强后肝衰减诊断性能优于肝脾衰减差(AUC 0.938 vs 0.832,p<.001)。

核心结论

  • 在异质性患者样本中,经自动化人工智能工具评估,增强后肝衰减检测至少中度肝脂肪变性的性能优于增强后肝脾衰减差;脾脏衰减可能不需要用于评估增强图像上的至少中度肝脂肪变性。

研究设计与样本

  • 回顾性研究,纳入2917例患者(男1381例,女1536例,平均年龄56.8岁),来自美国一个医疗网络24个中心和以色列一个医疗网络29个中心的人工智能供应商数据湖,使用自动化深度学习工具提取肝脏和脾脏衰减测量值,参考标准为平扫肝衰减<40 HU(即估计肝脂肪>15%)。

关键影像表现/征象

  • 无至少中度肝脂肪变性患者与有至少中度肝脂肪变性患者的增强后肝平均衰减分别为104.5±18.1 HU与67.1±18.6 HU(p<.001)。
  • 无至少中度肝脂肪变性患者与有至少中度肝脂肪变性患者的增强后肝脾衰减差分别为-7.6±16.4 HU与-31.8±20.3 HU(p<.001)。
  • 无至少中度肝脂肪变性患者与有至少中度肝脂肪变性患者的肝平均强化分别为49.3±15.9 HU与38.6±13.6 HU(p<.001)。

诊断标准与关键数值

  • 至少中度肝脂肪变性的参考标准为平扫肝衰减<40 HU(即估计肝脂肪>15%)。
  • 增强后肝衰减检测至少中度肝脂肪变性:AUC=0.938;<80 HU时敏感度77.8%、特异度93.2%;<90 HU时敏感度90.5%、特异度78.4%。
  • 增强后肝脾衰减差检测至少中度肝脂肪变性:AUC=0.832;<-20 HU时敏感度71.4%、特异度79.3%;<-10 HU时敏感度87.0%、特异度62.1%。
  • 增强后肝衰减的AUC高于增强后肝脾衰减差(AUC=0.938 vs 0.832,p<.001)。

临床应用与阅片要点

  • 门静脉期增强CT可用于评估至少中度肝脂肪变性,肝衰减测量值可辅助诊断。
  • 脾脏衰减可能不需要用于评估增强图像上的至少中度肝脂肪变性。
  • 该技术可能通过个体化或大规模机会性评估促进临床显著非酒精性脂肪性肝病的早期发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Precontrast CT is an established means of evaluating for hepatic steatosis; postcontrast CT has historically been limited for this purpose. OBJECTIVE. The purpose of this study was to evaluate the diagnostic performance of portal venous phase postcontrast CT in detecting at least moderate hepatic steatosis using liver and spleen attenuation measurements determined by an automated artificial intelligence (AI) tool. METHODS. This retrospective study included 2917 patients (1381 men, 1536 women; mean age, 56.8 years) who underwent a CT examination that included at least two series through the liver. Examinations were obtained from an AI vendor's data lake of data from 24 centers in one U.S. health care network and 29 centers in one Israeli health care network. An automated deep learning tool extracted liver and spleen attenuation measurements. The reference for at least moderate steatosis was precontrast liver attenuation of less than 40 HU (i.e., estimated liver fat > 15%). A radiologist manually reviewed examinations with outlier AI results to confirm portal venous timing and identify issues impacting attenuation measurements. RESULTS. After outlier review, analysis included 2777 patients with portal venous phase images. Prevalence of at least moderate steatosis was 13.9% (387/2777). Patients without and with at least moderate steatosis, respectively, had mean postcontrast liver attenuation of 104.5 ± 18.1 (SD) HU and 67.1 ± 18.6 HU (p < .001); a mean difference in postcontrast attenuation between the liver and the spleen (hereafter, postcontrast liver-spleen attenuation difference) of -7.6 ± 16.4 (SD) HU and -31.8 ± 20.3 HU (p < .001); and mean liver enhancement of 49.3 ± 15.9 (SD) HU versus 38.6 ± 13.6 HU (p < .001). Diagnostic performance for the detection of at least moderate steatosis was higher for postcontrast liver attenuation (AUC = 0.938) than for the postcontrast liver-spleen attenuation difference (AUC = 0.832) (p < .001). For detection of at least moderate steatosis, postcontrast liver attenuation had sensitivity and specificity of 77.8% and 93.2%, respectively, at less than 80 HU and 90.5% and 78.4%, respectively, at less than 90 HU; the postcontrast liver-spleen attenuation difference had sensitivity and specificity of 71.4% and 79.3%, respectively, at less than -20 HU and 87.0% and 62.1%, respectively, at less than -10 HU. CONCLUSION. Postcontrast liver attenuation outperformed the postcontrast liver-spleen attenuation difference for detecting at least moderate steatosis in a heterogeneous patient sample, as evaluated using an automated AI tool. Splenic attenuation likely is not needed to assess for at least moderate steatosis on postcontrast images. CLINICAL IMPACT. The technique could promote early detection of clinically significant nonalcoholic fatty liver disease through individualized or large-scale opportunistic evaluation.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Pickhardt PJ, Blake GM, Kimmel Y, et al. Detection of Moderate Hepatic Steatosis on Portal Venous Phase Contrast-Enhanced CT: Evaluation Using an Automated Artificial Intelligence Tool. AJR Am J Roentgenol. 2023. PMID: 37466185. doi:10.2214/AJR.23.29651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。